Trials / Conditions / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma

21 registered clinical trials studyying Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma.

Status	Trial	Sponsor	Phase
Terminated	SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes NCT02644122	Ezra Cohen	Phase 2
Completed	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	—
Completed	Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C NCT02035527	Ohio State University Comprehensive Cancer Center	Phase 1
Completed	PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT01816984	University of Chicago	Phase 1 / Phase 2
Completed	18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675	Sanjiv Sam Gambhir	Phase 1 / Phase 2
Terminated	Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Hea NCT01528137	Stanford University	Phase 1
Completed	TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squam NCT01334177	University of Washington	Phase 1
Completed	Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr NCT01316757	Fox Chase Cancer Center	Phase 2
Completed	Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck NCT01044433	Abramson Cancer Center at Penn Medicine	Phase 2
Completed	Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab NCT00939627	National Cancer Institute (NCI)	Phase 2
Terminated	Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360	National Cancer Institute (NCI)	Phase 1
Completed	Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. NCT01469429	Ohio State University Comprehensive Cancer Center	Phase 1 / Phase 2
Completed	Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00513435	National Cancer Institute (NCI)	Phase 2
Completed	Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00507767	National Cancer Institute (NCI)	Phase 2
Completed	Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT00387335	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00095628	National Cancer Institute (NCI)	Phase 2
Completed	S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00096512	National Cancer Institute (NCI)	Phase 2
Completed	Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck NCT00033618	National Cancer Institute (NCI)	Phase 2
Completed	Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00049283	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959	National Cancer Institute (NCI)	Phase 1